Fate Therapeutics, Inc.
NASDAQFate Therapeutics enters its May 14 earnings call riding an extraordinary week — the stock doubled on a regulatory catalyst while short sellers quietly trimmed positions and call buyers dominated the options market. The trigger was clear. On May 5, the FDA selected FATE for its Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to support…
Snapshot as of 7 May 2026
Fate Therapeutics enters its May 14 earnings call riding an extraordinary week — the stock doubled on a regulatory catalyst while short sellers quietly trimmed positions and call buyers dominated the options…
Fate Therapeutics enters its May 14 earnings date with an uncomfortable combination: short interest ticking higher over the past week, borrow availability loosening, and a stock down nearly 10% in seven days to $1.24.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for FATE — free to start on ORTEX.
Sign up for free →Open FATE on ORTEX